Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 05 2021 - 4:35PM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
“Company”), a specialty biopharmaceutical company developing and
commercializing a diversified portfolio of pharmaceutical and
diagnostic products, today announced the results from its Annual
General Meeting (“AGM”) held today, May 5, 2021.
The individuals noted below were elected as
directors of the Company. The report on voting results provided by
the Company’s transfer agent indicated the following:
Name of Nominee |
Votes For |
% |
Votes Withheld |
% |
Peter Edwards |
7,372,226 |
85.74 |
% |
1,226,203 |
14.26 |
% |
Carolyn Egbert |
7,536,307 |
87.65 |
% |
1,062,122 |
12.35 |
% |
Gilles Gagnon |
7,353,055 |
85.52 |
% |
1,245,374 |
14.48 |
% |
Klaus Paulini |
7,917,497 |
92.08 |
% |
680,932 |
7.92 |
% |
Dennis Turpin |
7,525,819 |
87.53 |
% |
1,072,610 |
12.47 |
% |
The Company would like to welcome Dennis Turpin
to the board of directors.
Ernst & Young LLP was also appointed as the
Company’s independent auditor at the AGM.
The Company is an “Eligible Interlisted Issuer”
as such term is defined in the TSX Company Manual. As an Eligible
Interlisted Issuer, the Company has relied on an exemption pursuant
to Section 602.1 of the TSX Company Manual from Section 613 of the
TSX Company Manual, the effect of which is that, subject to the
satisfaction of certain conditions prescribed by the Toronto Stock
Exchange, the Company will not have to comply with certain Canadian
requirements in connection with the Company’s long-term incentive
plan. As a result, shareholders were not asked to approve the
unallocated entitlements under the Company’s long-term incentive
plan at the AGM.
For full voting details please see the report of
voting results of Aeterna as filed on SEDAR at www.sedar.com and
EDGAR at www.sec.gov.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty
biopharmaceutical company developing and commercializing a
diversified portfolio of pharmaceutical and diagnostic products
focused on areas of significant unmet medical need. The Company’s
lead product, macimorelin, is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). The Company is
leveraging the clinical success and compelling safety profile of
macimorelin to develop it for the diagnosis of childhood-onset
growth hormone deficiency (CGHD) in collaboration with Novo
Nordisk.Aeterna Zentaris is dedicated to the development of
therapeutic assets and has recently taken steps to establish a
growing pipeline to address unmet medical needs across a number of
indications, including neuromyelitis optica spectrum disorder
(NMOSD), primary hypoparathyroidism and an undisclosed
neurodegenerative disease. Additionally, the Company is developing
an oral prophylactic bacterial vaccine against SARS-CoV-2, the
virus that causes COVID-19.
For more information, please visit
www.zentaris.com and connect with the Company on Twitter, LinkedIn
and Facebook.
Investor Contact:
Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2024 to Jun 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2023 to Jun 2024